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Computational Fluid Dynamics (CFD) is an established method in fluid mechanics that allows fluidic problems to 
be solved through numerical methods. In recent years, CFD has established itself as a useful tool in biochemical 
engineering, where it is mainly used to characterise and optimize devices (e.g. bioreactors, pumps, etc.). By 
using CFD, fundamental bioengineering parameters (e.g. turbulent dissipation rates, shear gradients) can be 
predicted independently of time and location. This allows process related parameters to be defined in silico, 
which reduces the number of experiments and costs. This is particularly important for the development of cell 
therapeutics, where the starting cell material is restricted and the batch costs are high. Recent economic reports 
have predicted a significant increase in cell therapeutics over the next few years, especially for human 
mesenchymal stem cells (hMSCs). This situation can also be seen in the high number of clinical trials (269 
trails, August 2016; clinicaltrails.gov) that are currently focusing on using hMSCs for the treatment of  illnesses 
such as myocardial infarction, Crohn’s disease and graft versus host disease. However, large amounts of 
hMSCs are required for one single therapeutic dose (35-350 million cells per dose), which explains the demand 
for efficient and scalable in vitro expansion procedures.  
 
Following a brief introduction to CFD, we aim to highlight the capabilities of CFD for the development of 
bioprocesses and scale-up procedures. For this purpose, we will show how CFD data can be used to support 
the scale-up of a microcarrier-based hMSC expansion process in stirred and wave-mixed single-use 
bioreactors. Our presented investigations involve Computational Fluid Dynamics (CFD) simulations and data 
verification using Particle Image Velocimetry (PIV) measurements, suspension studies in a serum-reduced 
culture medium with a suitable polystyrene microcarrier, and expansion studies with human adipose tissue-
derived stromal/stem cells (hASCs). This combination of biochemical engineering and biological expertise 
enabled the establishment of a MC-based hMSC expansion process that resulted in up to 1.25 x 106 
hMSCs/mL in stirred single-use bioreactors. Initial proof-of-concept expansions of hASCs in wave-mixed single-
use bioreactors at a rocking angle/ -rate combination of 4° and 31 rpm resulted in the harvest of 2.85 x 108 
hASCs after 9 days of cultivation without changes to the stem cell characteristics. All the investigations 
performed showed that the suspension criteria NS1U for stirred and NS1UW for wave-mixed bioreactors are 
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